New HIV pill CL-197 shows promise in early trial for untreated patients
NCT ID NCT07308782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing an experimental drug called CL-197 in 24 adults with HIV-1 who have never taken any anti-HIV drugs. The goal is to see if a single dose can lower the amount of virus in the blood and to check for side effects. Participants will be monitored for about two weeks. This is an early-phase study, so it focuses on safety and how the drug works, not on a long-term cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Youan Hospital, Capital Medical University
RECRUITINGBeijing, China